// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

ASIA PACIFIC SURVEY OF PHYSICIANS ON ASTHMA AND ALLERGIC RHINITIS (ASPAIR): DATA FOR THREE HYPOTHETICAL CASE STUDIES

BHUMIKA AGGARWAL - Asian Pacific Society of Respirology (APSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Allergic rhinitis

N/A

Treatment-Induced Reductions in Cerebrospinal Fluid Neurofilament Light Levels are Age-Dependent in Multiple Sclerosis

I. Smets - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

N/A

Effectiveness, Safety and Patient-reported Outcomes of Ofatumumab in Relapsing Multiple Sclerosis Patients Switching from Dimethyl Fumarate or Fingolimod: ARTIOS Phase 3b Study Design

M. Craner - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

Dimethyl fumarate

Analysis of Lymphocyte Subsets in Younger and Older Patients with Multiple Sclerosis Treated with Cladribine Tablets

G. Giovannoni - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

Cladribine

Analysis of Infection in Younger and Older Patients with Multiple Sclerosis Treated with Cladribine Tablets who had Grade ≥3 Lymphopenia

P. K. Coyle - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Multiple Sclerosis

Cladribine

Iron Rims as an Imaging Biomarker in MS: A Systematic Mapping Review

A. I. Altokhis - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Cladribine Personalised Dosing to Treat Active Multiple Sclerosis - Follow-up in 250 patients

K. Allen-Philbey - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Multiple Sclerosis

Cladribine

Lymphotoxin alpha overexpression in the meninges causes lymphoid-like tissue development and subsequent neurodegeneration

R. E. James - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Interferon Gamma

The role of neuronal CXCL13 chemokine expression in Multiple Sclerosis Pathology

R. E. James - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

N/A

Patient and Nurse Preferences for Sensoready® Autoinjector Pen Versus Other Autoinjectors in Multiple Sclerosis: Results from a Multicenter Survey

A. Ross - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

Avonex

Nabiximols, a cannabis-based complex botanical mixture and MS spasticity: How does it work?

K. Nichol - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Efficacy and Safety of Crisaborole in Patients With Mild-to-Moderate Atopic Dermatitis With Comorbid Allergic Rhinitis or Asthma

Jonathan Spergel - American Academy of Allergy, Asthma, and Immunology (AAAAI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Allergic rhinitis

Crisaborole

Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials

Mark Liu - American Academy of Allergy, Asthma, and Immunology (AAAAI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Mepolizumab

CAPTAIN: Effects of Body Mass Index (BMI) on Response to Triple Therapy in Patients With Inadequately Controlled Asthma on Inhaled Corticosteroids/Long-acting β2-agonists (ICS/LABA)

Diego Maselli - American Academy of Allergy, Asthma, and Immunology (AAAAI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Umeclidinium

CAPTAIN: Effects of Cardiovascular Risk on Response to Triple Therapy in Patients With Inadequately Controlled Asthma on Inhaled Corticosteroids/Long-acting β2-agonists (ICS/LABA)

Nicola Hanania - American Academy of Allergy, Asthma, and Immunology (AAAAI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Congestive heart failure

Umeclidinium

Cough Triggers and Symptoms Among Patients with Refractory or Unexplained Chronic Cough in Two Phase 3 Trials of the P2X3 Receptor Antagonist Gefapixant (COUGH-1 and COUGH-2)

Alyn Morice - American Academy of Allergy, Asthma, and Immunology (AAAAI) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Gefapixant

Comorbid Conditions and Medical History Among Patients with Refractory or Unexplained Chronic Cough in Two Phase 3 Clinical Trials (COUGH-1 and COUGH-2)

Peter Dicpinigaitis - American Academy of Allergy, Asthma, and Immunology (AAAAI) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Assessment of reduction of the PM 2.5 and fungal spores using AFL Facemask

Nabarun Ghosh - American Academy of Allergy, Asthma, and Immunology (AAAAI) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Safety of Peanut (Arachis Hypogaea) Allergen Powder-dnfp in Children and Teenagers With Peanut Allergy: Pooled Analysis From Controlled and Open-Label Phase 3 Trials

Thomas Casale - American Academy of Allergy, Asthma, and Immunology (AAAAI) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Mepolizumab Improves Health Related Quality of Life for Patients with Chronic Rhinosinusitis with Nasal Polyps: Data from the SYNAPSE study

Stella Lee - American Academy of Allergy, Asthma, and Immunology (AAAAI) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Mepolizumab

Copyright © 2026. QuantiNova All rights reserved